RNA, U6 small nuclear 250, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-250P profile across patient tissues and cancer cell-line models. RNU6-250P expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RNU6-250P is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, RNU6-250P RNA expression shows 7,644 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight LIHC, BRCA, and COAD as cancer lineages where RNU6-250P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-250P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-250P survival associations across molecular data types. RNU6-250P RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-250P RNA expression–survival associations across cancer types. High RNU6-250P expression shows unfavorable associations in LIHC, HNSC, KIRC, STAD, SKCM and BRCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RNU6-250P RNA expression.
This table summarizes RNU6-250P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-250P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-250P shows higher tumor expression in BRCA. The BRCA box plot shows higher RNU6-250P RNA expression in tumor versus normal tissue (log2 FC = +0.288, t-test p < 0.001).
This table shows molecular features associated with RNU6-250P in patient tissues and cancer cell lines. In patient samples, RNU6-250P shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
